Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825 is registered in ClinicalTrials.gov with Novelty Nobility, Inc. as lead sponsor.

NCT NCT06805825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06805825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose Escalation and Expansion Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 in Subjects With Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Lead sponsor
Novelty Nobility, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
February 3, 2025
Completion date
December 31, 2027
Enrollment
67 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenoid cystic carcinoma, chromophobe renal cell carcinoma, clear cell renal cell carcinoma, gastrointestinal stromal tumors, neuroendocrine tumors, small-cell lung cancer, uveal melanoma